US FDA delivers a Form 483 with four observations to Sun Pharma, with one noting that the company took eight years to create design plans for the production of one product.
The Indian firm is relocating manufacturing operations in New Jersey, from its Cranbury facility to New Brunswick, in an effort to “improve cost efficiencies” across the US.
Sun Pharmaceutical Industries has completed its $4bn (€3.7bn) acquisition of Ranbaxy after receiving the thumbs up from the US Federal Trade Commission (FTC).
Sun Pharma says the closure of a Michigan plant employing 179 staff is necessary in order to consolidate its US manufacturing network, and not related to its Ranbaxy acquisition.
Regulatory compliance will be the number one focus for Sun Pharma, the company says, following its $3.2bn (€2.3bn) takeover of Indian generics firm Ranbaxy.
Sun Pharma’s antibiotic facility import alert is the latest blow to the Indian drug industry but is unlikely to impact revenues or cause US shortages, the firm says.
A white knight in the form of Indian-based Sun Pharmaceuticals, has
rescued an Israeli company from a looming financial crisis by
investing more than $400m in the company.
Sun Pharma of India has provided additional details of its plans
for its new facility in Hungary, purchased in August and intended
as a springboard to launch the company's ambitions in Europe and
around the world, and its recently-acquired...
Sun Pharmaceutical Industries has become the second Indian
drugmaker in a matter of days to announce the purchase of a
manufacturing facility in Eastern Europe that will serve as a
springboard for expansion into the broader European...
